SLRX Salarius Pharmaceuticals Inc.

1.18
+0.02  (+2%)
Previous Close 1.16
Open 1.21
Price To Book 0.89
Market Cap 16,107,887
Shares 13,650,752
Volume 529,053
Short Ratio
Av. Daily Volume 409,045
Stock charts supplied by TradingView

NewsSee all news

  1. Salarius Pharmaceuticals Reports First Quarter 2020 Financial Results

    Seclidemstat Advances Dose Escalation in Phase 1/2 Ewing Sarcoma Clinical Trial; On Track to Report Early Data in 2020 Conference Call and Live Audio Webcast Scheduled for Today, May 14, 2020, at 4:30 p.m. ET

  2. Salarius Pharmaceuticals Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program

    HOUSTON, May 14, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced today that an abstract

  3. Salarius Pharmaceuticals to Report First Quarter 2020 Financial Results

    HOUSTON, May 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today announced that the Company

  4. Salarius Pharmaceuticals Announces Board of Director Nominations in Advance of 2020 Annual Meeting

    HOUSTON, April 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today announced that its Board

  5. Salarius Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results

    Seclidemstat Achieves Dose-Escalation Milestone in Phase 1/2 Ewing Sarcoma Clinical Trial Sixth Level Dosing Cohort Now Proceeding; On Track To Report Topline Data in 2020 HOUSTON, March 23, 2020 (GLOBE NEWSWIRE)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data due before the end of 2020.
Seclidemstat
Solid tumors
Phase 1/2 presentation at ASCO May 29, 2020.
Seclidemstat
Ewing sarcoma

Latest News

  1. Salarius Pharmaceuticals Reports First Quarter 2020 Financial Results

    Seclidemstat Advances Dose Escalation in Phase 1/2 Ewing Sarcoma Clinical Trial; On Track to Report Early Data in 2020 Conference Call and Live Audio Webcast Scheduled for Today, May 14, 2020, at 4:30 p.m. ET

  2. Salarius Pharmaceuticals Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program

    HOUSTON, May 14, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced today that an abstract

  3. Salarius Pharmaceuticals to Report First Quarter 2020 Financial Results

    HOUSTON, May 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today announced that the Company

  4. Salarius Pharmaceuticals Announces Board of Director Nominations in Advance of 2020 Annual Meeting

    HOUSTON, April 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today announced that its Board

  5. Salarius Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results

    Seclidemstat Achieves Dose-Escalation Milestone in Phase 1/2 Ewing Sarcoma Clinical Trial Sixth Level Dosing Cohort Now Proceeding; On Track To Report Topline Data in 2020 HOUSTON, March 23, 2020 (GLOBE NEWSWIRE)

  6. Salarius Announces Allowance of New European Patent Covering Seclidemstat

    European Patent Office Satisfied Patent Application Meets All Requirements Salarius' Global Intellectual Property Estate Includes 22 Issued Patents in the U.S., Europe and 12 Other Jurisdictions HOUSTON, March 04,

  7. Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference

    HOUSTON, March 02, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its chief

  8. Salarius Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

    HOUSTON, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the closing of its

  9. Salarius Pharmaceuticals to Present at the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference

    HOUSTON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief

  10. Salarius Announces Pricing of $9.6 Million Underwritten Public Offering

    HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of an underwritten

  11. Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors

    Seclidemstat Modulates Tumor Microenvironment to Help Genetically Mutated Cancer Types Overcome Resistance to Checkpoint Inhibitors in Preclinical Study Data Supports Continued Study of Seclidemstat with Checkpoint

  12. Salarius Pharmaceuticals to Present at Biotech Showcase 2020

    HOUSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred to as epigenetics,

  13. Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression

    HOUSTON, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it will host a key opinion

  14. Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma

    HOUSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its lead

  15. Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results

    HOUSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, today reported its corporate and financial

  16. MicroCap Rodeo Investor Conference - Lineup for October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16th, 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, the MicroCap

  17. Salarius Pharmaceuticals to Present at Two Upcoming Investor Conferences

    HOUSTON, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced its participation at two upcoming

  18. Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children's Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma

    HOUSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that Memorial Sloan Kettering

  19. Salarius Pharmaceuticals Achieves Dose-Escalation Milestones in Ongoing Phase 1/2 Ewing Sarcoma and Phase 1 Advanced Solid Tumor Clinical Trials

    HOUSTON, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that the Safety Review Committees

  20. Salarius Pharmaceuticals Announces Senior Leadership Changes

    HOUSTON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the appointment of Scott Jordan to

  21. Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month

    HOUSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, announced its support for Childhood Cancer

  22. Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month

    HOUSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, announced its support for Childhood Cancer